{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T04:09:05Z","timestamp":1767499745655},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,5,24]],"date-time":"2012-05-24T00:00:00Z","timestamp":1337817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00277-012-1493-3","type":"journal-article","created":{"date-parts":[[2012,7,22]],"date-time":"2012-07-22T02:56:34Z","timestamp":1342925794000},"page":"1823-1824","source":"Crossref","is-referenced-by-count":18,"title":["Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFR\u03b2 rearrangement and type 1 diabetes"],"prefix":"10.1007","volume":"91","author":[{"given":"Adriano","family":"Salaroli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Loglisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Serrao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,24]]},"reference":[{"key":"1493_CR1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/CS20090348","volume":"118","author":"D Mokhtari","year":"2009","unstructured":"Mokhtari D, Welsh N (2009) Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 118:241\u2013247","journal-title":"Clin Sci (Lond)"},{"key":"1493_CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1078155210378913","volume":"17","author":"NM Agostino","year":"2011","unstructured":"Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ (2011) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. J Oncol Pharm Pract 17:197\u2013202","journal-title":"J Oncol Pharm Pract"},{"key":"1493_CR3","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","volume":"22","author":"M Breccia","year":"2004","unstructured":"Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G (2004) Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 22:4653\u20134655","journal-title":"J Clin Oncol"},{"key":"1493_CR4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.leukres.2009.01.040","volume":"33","author":"M Breccia","year":"2009","unstructured":"Breccia M, Alimena G (2009) The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism. Leuk Res 33:871\u2013875","journal-title":"Leuk Res"},{"key":"1493_CR5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/000313480607201216","volume":"72","author":"J Guiteau","year":"2006","unstructured":"Guiteau J, Fanucchi M, Folpe A, Staley CA 3rd, Kooby DA (2006) Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. Am Surg 72:1225\u20131230","journal-title":"Am Surg"},{"key":"1493_CR6","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1200\/JCO.2006.06.5318","volume":"24","author":"P Hamberg","year":"2006","unstructured":"Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweji J, Sleijfer S (2006) Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 24:e30\u2013e31","journal-title":"J Clin Oncol"},{"key":"1493_CR7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1096\/fj.06-6910com","volume":"21","author":"R H\u00e4gerkvist","year":"2007","unstructured":"H\u00e4gerkvist R, Sandler S, Mokhtari D, Welsh N (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic pre-conditioning. FASEB J 21:618\u2013628","journal-title":"FASEB J"},{"key":"1493_CR8","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1210\/jc.2010-0086","volume":"95","author":"S Fitter","year":"2010","unstructured":"Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95:3763\u20133767","journal-title":"J Clin Endocrinol Metab"},{"key":"1493_CR9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4158\/EP.13.2.126","volume":"13","author":"D Dingli","year":"2007","unstructured":"Dingli D, Wolf RC, Vella A (2007) Imatinib and type 2 diabetes. Endocr Pract 13:126\u2013130","journal-title":"Endocr Pract"},{"key":"1493_CR10","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","volume":"105","author":"C Louvet","year":"2008","unstructured":"Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in non-obese diabetic mice. Proc Natl Acad Sci U S A 105:18895\u201318900","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1493-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-012-1493-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1493-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T16:11:32Z","timestamp":1642867892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1493-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,24]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1493-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,24]]}}}